• 1
    Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009. J Allergy Clin Immunol 2010;125:1629 e1–11; quiz 30–31.
  • 2
    Schultz Larsen F. Atopic dermatitis: a genetic-epidemiologic study in a population-based twin sample. J Am Acad Dermatol 1993;28(5 Pt 1):719723.
  • 3
    Strachan DP, Wong HJ, Spector TD. Concordance and interrelationship of atopic diseases and markers of allergic sensitization among adult female twins. J Allergy Clin Immunol 2001;108:901907.
  • 4
    Baurecht H, Irvine AD, Novak N, Illig T, Buhler B, Ring J et al. Toward a major risk factor for atopic eczema: meta-analysis of filaggrin polymorphism data. J Allergy Clin Immunol 2007;120:14061412.
  • 5
    Fallon PG, Sasaki T, Sandilands A, Campbell LE, Saunders SP, Mangan NE et al. A homozygous frameshift mutation in the mouse Flg gene facilitates enhanced percutaneous allergen priming. Nat Genet 2009;41:602608.
  • 6
    De Benedetto A, Qualia CM, Baroody FM, Beck LA. Filaggrin expression in oral, nasal, and esophageal mucosa. J Invest Dermatol 2008;128:15941597.
  • 7
    McLean WH, Palmer CN, Henderson J, Kabesch M, Weidinger S, Irvine AD. Filaggrin variants confer susceptibility to asthma. J Allergy Clin Immunol 2008;121:12941295; author reply 1295-6.
  • 8
    Bisgaard H, Simpson A, Palmer CN, Bonnelykke K, McLean I, Mukhopadhyay S et al. Gene-environment interaction in the onset of eczema in infancy: filaggrin loss-of-function mutations enhanced by neonatal cat exposure. PLoS Med 2008;5:e131.
  • 9
    Schuttelaar ML, Kerkhof M, Jonkman MF, Koppelman GH, Brunekreef B, de Jongste JC et al. Filaggrin mutations in the onset of eczema, sensitization, asthma, hay fever and the interaction with cat exposure. Allergy 2009;64:17581765.
  • 10
    Brandt EB, Sivaprasad U. Th2 cytokines and atopic dermatitis. J Clin Cell Immunol 2011;2:pii:110.
  • 11
    Deleuran M, Hvid M, Kemp K, Christensen GB, Deleuran B, Vestergaard C. IL-25 induces both inflammation and skin barrier dysfunction in atopic dermatitis. Chem Immunol Allergy 2012;96:4549.
  • 12
    Gschwandtner M, Mildner M, Mlitz V, Gruber F, Eckhart L, Werfel T et al. Histamine suppresses epidermal keratinocyte differentiation and impairs skin barrier function in a human skin model. Allergy 2013;68:3747.
  • 13
    Howell MD, Kim BE, Gao P, Grant AV, Boguniewicz M, DeBenedetto A et al. Cytokine modulation of atopic dermatitis filaggrin skin expression. J Allergy Clin Immunol 2009;124(3 Suppl 2):R7R12.
  • 14
    Howell MD, Fairchild HR, Kim BE, Bin L, Boguniewicz M, Redzic JS et al. Th2 cytokines act on S100/A11 to downregulate keratinocyte differentiation. J Invest Dermatol 2008;128:22482258.
  • 15
    Grewe M, Walther S, Gyufko K, Czech W, Schopf E, Krutmann J. Analysis of the cytokine pattern expressed in situ in inhalant allergen patch test reactions of atopic dermatitis patients. J Invest Dermatol 1995;105:407410.
  • 16
    Eyerich K, Bockelmann R, Pommer AJ, Foerster S, Hofmeister H, Huss-Marp J et al. Comparative in situ topoproteome analysis reveals differences in patch test-induced eczema: cytotoxicity-dominated nickel versus pleiotrope pollen reaction. Exp Dermatol 2010;19:511517.
  • 17
    Morizane S, Yamasaki K, Kajita A, Ikeda K, Zhan M, Aoyama Y et al. TH2 cytokines increase kallikrein 7 expression and function in patients with atopic dermatitis. J Allergy Clin Immunol 2012;130:259261 e1.
  • 18
    Suarez-Farinas M, Tintle SJ, Shemer A, Chiricozzi A, Nograles K, Cardinale I et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 2011;127:954964 e1–4.
  • 19
    Eyerich S, Onken AT, Weidinger S, Franke A, Nasorri F, Pennino D et al. Mutual antagonism of T cells causing psoriasis and atopic eczema. N Engl J Med 2011;365:231238.
  • 20
    Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995;32:982986.
  • 21
    Darsow U, Vieluf D, Ring J. Atopy patch test with different vehicles and allergen concentrations: an approach to standardization. J Allergy Clin Immunol 1995;95:677684.
  • 22
    Tintle S, Shemer A, Suarez-Farinas M, Fujita H, Gilleaudeau P, Sullivan-Whalen M et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 2011;128:583593 e1–4.
  • 23
    Bieber T. Atopic dermatitis. N Engl J Med 2008;358:14831494.
  • 24
    Eyerich K, Huss-Marp J, Darsow U, Wollenberg A, Foerster S, Ring J et al. Pollen grains induce a rapid and biphasic eczematous immune response in atopic eczema patients. Int Arch Allergy Immunol 2008;145:213223.
  • 25
    Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases. N Engl J Med 2011;365:13151327.
  • 26
    Walley AJ, Chavanas S, Moffatt MF, Esnouf RM, Ubhi B, Lawrence R et al. Gene polymorphism in Netherton and common atopic disease. Nat Genet 2001;29:175178.
  • 27
    Novak N, Baurecht H, Schafer T, Rodriguez E, Wagenpfeil S, Klopp N et al. Loss-of-function mutations in the filaggrin gene and allergic contact sensitization to nickel. J Invest Dermatol 2008;128:14301435.
  • 28
    Kasraie S, Niebuhr M, Baumert K, Werfel T. Functional effects of interleukin 31 in human primary keratinocytes. Allergy 2011;66:845852.
  • 29
    Kasraie S, Niebuhr M, Kopfnagel V, Dittrich-Breiholz O, Kracht M, Werfel T. Macrophages from patients with atopic dermatitis show a reduced CXCL10 expression in response to staphylococcal alpha-toxin. Allergy 2012;67:4149.
  • 30
    Liu YJ, Soumelis V, Watanabe N, Ito T, Wang YH, Malefyt RdeW et al. TSLP: an epithelial cell cytokine that regulates T cell differentiation by conditioning dendritic cell maturation. Annu Rev Immunol 2007;25:193219.
  • 31
    Ong PY, Ohtake T, Brandt C, Strickland I, Boguniewicz M, Ganz T et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 2002;347:11511160.
  • 32
    Eyerich K, Pennino D, Scarponi C, Foerster S, Nasorri F, Behrendt H et al. IL-17 in atopic eczema: linking allergen-specific adaptive and microbial-triggered innate immune response. J Allergy Clin Immunol 2009;123:5966 e4.
  • 33
    Gros E, Petzold S, Maintz L, Bieber T, Novak N. Reduced IFN-gamma receptor expression and attenuated IFN-gamma response by dendritic cells in patients with atopic dermatitis. J Allergy Clin Immunol 2011;128:10151021.
  • 34
    Leung DY, Gao PS, Grigoryev DN, Rafaels NM, Streib JE, Howell MD et al. Human atopic dermatitis complicated by eczema herpeticum is associated with abnormalities in IFN-gamma response. J Allergy Clin Immunol 2011;127:965973 e1–5.
  • 35
    Gao PS, Leung DY, Rafaels NM, Boguniewicz M, Hand T, Gao L et al. Genetic variants in interferon regulatory factor 2 (IRF2) are associated with atopic dermatitis and eczema herpeticum. J Invest Dermatol 2012;132(3 Pt 1):650657.
  • 36
    Hinz D, Bauer M, Roder S, Olek S, Huehn J, Sack U et al. Cord blood Tregs with stable FOXP3 expression are influenced by prenatal environment and associated with atopic dermatitis at the age of one year. Allergy 2012;67:380389.
  • 37
    Novak N. New insights into the mechanism and management of allergic diseases: atopic dermatitis. Allergy 2009;64:265275.
  • 38
    Novak N, Peng WM, Bieber T, Akdis C. FcepsilonRI stimulation promotes the differentiation of histamine receptor 1-expressing inflammatory macrophages. Allergy 2013;68:454461.
  • 39
    Peng WM, Yu CF, Kolanus W, Mazzocca A, Bieber T, Kraft S et al. Tetraspanins CD9 and CD81 are molecular partners of trimeric FcvarepsilonRI on human antigen-presenting cells. Allergy 2011;66:605611.
  • 40
    Gros E, Bussmann C, Bieber T, Forster I, Novak N. Expression of chemokines and chemokine receptors in lesional and nonlesional upper skin of patients with atopic dermatitis. J Allergy Clin Immunol 2009;124:753760 e1.
  • 41
    Kwiek B, Peng WM, Allam JP, Langner A, Bieber T, Novak N. Tacrolimus and TGF-beta act synergistically on the generation of Langerhans cells. J Allergy Clin Immunol 2008;122:126132, 132 e1.
  • 42
    Pilette C, Jacobson MR, Ratajczak C, Detry B, Banfield G, VanSnick J et al. Aberrant dendritic cell function conditions Th2-cell polarization in allergic rhinitis. Allergy 2013;68:312321.
  • 43
    Fujita H, Shemer A, Suarez-Farinas M, Johnson-Huang LM, Tintle S, Cardinale I et al. Lesional dendritic cells in patients with chronic atopic dermatitis and psoriasis exhibit parallel ability to activate T-cell subsets. J Allergy Clin Immunol 2011;128:574582 e1–12.
  • 44
    Trompette A, Divanovic S, Visintin A, Blanchard C, Hegde RS, Madan R et al. Allergenicity resulting from functional mimicry of a Toll-like receptor complex protein. Nature 2009;457:585588.
  • 45
    Chiou YL, Lin CY. Der p2 activates airway smooth muscle cells in a TLR2/MyD88-dependent manner to induce an inflammatory response. J Cell Physiol 2009;220:311318.
  • 46
    Schmidt M, Raghavan B, Muller V, Vogl T, Fejer G, Tchaptchet S et al. Crucial role for human Toll-like receptor 4 in the development of contact allergy to nickel. Nat Immunol 2010;11:814819.
  • 47
    Martin SF, Esser PR, Weber FC, Jakob T, Freudenberg MA, Schmidt M et al. Mechanisms of chemical-induced innate immunity in allergic contact dermatitis. Allergy 2011;66:11521163.
  • 48
    Traidl-Hoffmann C, Mariani V, Hochrein H, Karg K, Wagner H, Ring J et al. Pollen-associated phytoprostanes inhibit dendritic cell interleukin-12 production and augment T helper type 2 cell polarization. J Exp Med 2005;201:627636.
  • 49
    Traidl-Hoffmann C, Kasche A, Jakob T, Huger M, Plotz S, Feussner I et al. Lipid mediators from pollen act as chemoattractants and activators of polymorphonuclear granulocytes. J Allergy Clin Immunol 2002;109:831838.
  • 50
    Metz M, Gilles S, Geldmacher A, Behrendt H, Traidl-Hoffmann C, Maurer M. Evidence for non-allergic mast cell activation in pollen-associated inflammation. J Invest Dermatol 2011;131:987990.
  • 51
    Jiang H, Hener P, Li J, Li M. Skin thymic stromal lymphopoietin promotes airway sensitization to inhalant house dust mites leading to allergic asthma in mice. Allergy 2012;67:10781082.
  • 52
    Oyoshi MK, Larson RP, Ziegler SF, Geha RS. Mechanical injury polarizes skin dendritic cells to elicit a T(H)2 response by inducing cutaneous thymic stromal lymphopoietin expression. J Allergy Clin Immunol 2010;126:976984, 984 e1–5.
  • 53
    Kinoshita H, Takai T, Le TA, Kamijo S, Wang XL, Ushio H et al. Cytokine milieu modulates release of thymic stromal lymphopoietin from human keratinocytes stimulated with double-stranded RNA. J Allergy Clin Immunol 2009;123:179186.
  • 54
    Vu AT, Baba T, Chen X, Le TA, Kinoshita H, Xie Y et al. Staphylococcus aureus membrane and diacylated lipopeptide induce thymic stromal lymphopoietin in keratinocytes through the Toll-like receptor 2-Toll-like receptor 6 pathway. J Allergy Clin Immunol 2010;126:985993, 993 e1–3.
  • 55
    Gittler JK, Shemer A, Suarez-Farinas M, Fuentes-Duculan J, Gulewicz KJ, Wang CQ et al. Progressive activation of T(H)2/T(H)22 cytokines and selective epidermal proteins characterizes acute and chronic atopic dermatitis. J Allergy Clin Immunol 2012;130:13441354.
  • 56
    Nograles KE, Zaba LC, Shemer A, Fuentes-Duculan J, Cardinale I, Kikuchi T et al. IL-22-producing “T22” T cells account for upregulated IL-22 in atopic dermatitis despite reduced IL-17-producing TH17 T cells. J Allergy Clin Immunol 2009;123:12441252 e2.
  • 57
    Fischer-Stabauer M, Boehner A, Eyerich S, Carbone T, Traidl-Hoffmann C, Schmidt-Weber CB et al. Differential in situ expression of IL-17 in skin diseases. Eur J Dermatol 2012;22:781784.
  • 58
    Kong HH, Oh J, Deming C, Conlan S, Grice EA, Beatson MA et al. Temporal shifts in the skin microbiome associated with disease flares and treatment in children with atopic dermatitis. Genome Res 2012;22:850859.
  • 59
    Herrmann N, Koch S, Leib N, Bedorf J, Wilms H, Schnautz S et al. TLR2 down-regulates FcepsilonRI and its transcription factor PU.1 in human Langerhans cells. Allergy 2013;68:621626.
  • 60
    Macias ES, Pereira FA, Rietkerk W, Safai B. Superantigens in dermatology. J Am Acad Dermatol 2011;64:455472; quiz 473–474.
  • 61
    Niebuhr M, Scharonow H, Gathmann M, Mamerow D, Werfel T. Staphylococcal exotoxins are strong inducers of IL-22: a potential role in atopic dermatitis. J Allergy Clin Immunol 2012;126:11761183 e4.
  • 62
    Sonkoly E, Muller A, Lauerma AI, Pivarcsi A, Soto H, Kemeny L et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 2006;117:411417.
  • 63
    Eyerich S, Eyerich K, Pennino D, Carbone T, Nasorri F, Pallotta S et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest 2009;119:35733585.
  • 64
    Eyerich S, Eyerich K, Cavani A, Schmidt-Weber C. IL-17 and IL-22: siblings, not twins. Trends Immunol 2010;31:354361.
  • 65
    Mayser P, Gross A. IgE antibodies to Malassezia furfur, M. sympodialis and Pityrosporum orbiculare in patients with atopic dermatitis, seborrheic eczema or pityriasis versicolor, and identification of respective allergens. Acta Derm Venereol 2000;80:357361.
  • 66
    Bunikowski R, Mielke ME, Skarabis H, Worm M, Anagnostopoulos I, Kolde G et al. Evidence for a disease-promoting effect of Staphylococcus aureus-derived exotoxins in atopic dermatitis. J Allergy Clin Immunol 2000;105:814819.
  • 67
    Kortekangas-Savolainen O, Peltonen S, Pummi K, Kalimo K, Savolainen J. IgE-binding components of cultured human keratinocytes in atopic eczema/dermatitis syndrome and their crossreactivity with Malassezia furfur. Allergy 2004;59:168173.
  • 68
    Zeller S, Rhyner C, Meyer N, Schmid-Grendelmeier P, Akdis CA, Crameri R. Exploring the repertoire of IgE-binding self-antigens associated with atopic eczema. J Allergy Clin Immunol 2009;124:278285, 285 e1–7.
  • 69
    Crameri R, Faith A, Hemmann S, Jaussi R, Ismail C, Menz G et al. Humoral and cell-mediated autoimmunity in allergy to Aspergillus fumigatus. J Exp Med 1996;184:265270.
  • 70
    Heratizadeh A, Mittermann I, Balaji H, Wichmann K, Niebuhr M, Valenta R et al. The role of T-cell reactivity towards the autoantigen alpha-NAC in atopic dermatitis. Br J Dermatol 2011;164:316324.
  • 71
    Pennino D, Eyerich K, Scarponi C, Carbone T, Eyerich S, Nasorri F et al. IL-17 amplifies human contact hypersensitivity by licensing hapten nonspecific Th1 cells to kill autologous keratinocytes. J Immunol 2010;184:48804888.
  • 72
    Compalati E, Rogkakou A, Passalacqua G, Canonica GW. Evidences of efficacy of allergen immunotherapy in atopic dermatitis: an updated review. Curr Opin Allergy Clin Immunol 2012;12:427433.
  • 73
    Sheinkopf LE, Rafi AW, Do LT, Katz RM, Klaustermeyer WB. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008;29:530537.
  • 74
    Belloni B, Ziai M, Lim A, Lemercier B, Sbornik M, Weidinger S et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007;120:12231225.
  • 75
    Kasperkiewicz M, Schmidt E, Frambach Y, Rose C, Meier M, Nitschke M et al. Improvement of treatment-refractory atopic dermatitis by immunoadsorption: a pilot study. J Allergy Clin Immunol 2011;127:267270, 270 e1–6.
  • 76
    Jee SJ, Kim JH, Baek HS, Lee HB, Oh JW. Long-term efficacy of intravenous immunoglobulin therapy for moderate to severe childhood atopic dermatitis. Allergy Asthma Immunol Res 2011;3:8995.
  • 77
    Simon D, Hosli S, Kostylina G, Yawalkar N, Simon HU. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol 2008;121:122128.
  • 78
    Sediva A, Kayserova J, Vernerova E, Polouckova A, Capkova S, Spisek R et al. Anti-CD20 (rituximab) treatment for atopic eczema. J Allergy Clin Immunol 2008;121:15151516; author reply 1516–1517.
  • 79
    Oldhoff JM, Darsow U, Werfel T, Katzer K, Wulf A, Laifaoui J et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 2005;60:693696.
  • 80
    Imaizumi A, Kawakami T, Murakami F, Soma Y, Mizoguchi M. Effective treatment of pruritus in atopic dermatitis using H1 antihistamines (second-generation antihistamines): changes in blood histamine and tryptase levels. J Dermatol Sci 2003;33:2329.
  • 81
    Antoniu SA. Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema. Curr Opin Investig Drugs 2010;11:12861294.
  • 82
    Lau S, Gerhold K, Zimmermann K, Ockeloen CW, Rossberg S, Wagner P et al. Oral application of bacterial lysate in infancy decreases the risk of atopic dermatitis in children with 1 atopic parent in a randomized, placebo-controlled trial. J Allergy Clin Immunol 2012;129:10401047.
  • 83
    Roduit C, Frei R, Loss G, Buchele G, Weber J, Depner M et al. Development of atopic dermatitis according to age of onset and association with early-life exposures. J Allergy Clin Immunol 2012;130:130136 e5.
  • 84
    Jacobi A, Antoni C, Manger B, Schuler G, Hertl M. Infliximab in the treatment of moderate to severe atopic dermatitis. J Am Acad Dermatol 2005;52(3 Pt 1):522526.
  • 85
    Buka RL, Resh B, Roberts B, Cunningham BB, Friedlander S. Etanercept is minimally effective in 2 children with atopic dermatitis. J Am Acad Dermatol 2005;53:358359.
  • 86
    Puya R, Alvarez-Lopez M, Velez A, Casas Asuncion E, Moreno JC. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol 2012;51:115116.
  • 87
    Navarini AA, French LE, Hofbauer GF. Interrupting IL-6-receptor signaling improves atopic dermatitis but associates with bacterial superinfection. J Allergy Clin Immunol 2011;128:11281130.
  • 88
    Garmhausen D, Hagemann T, Bieber T, Dimitriou I, Fimmers R, Diepgen T et al. Characterization of different courses of atopic dermatitis in adolescent and adult patients. Allergy 2013;68:498506.
  • 89
    Bieber T. Atopic dermatitis 2.0: from the clinical phenotype to the molecular taxonomy and stratified medicine. Allergy 2012;67:14751482.
  • 90
    Bieber T, Cork M, Reitamo S. Atopic dermatitis: a candidate for disease-modifying strategy. Allergy 2012;67:969975.
  • 91
    Novak N, Simon D. Atopic dermatitis - from new pathophysiologic insights to individualized therapy. Allergy 2011;66:830839.
  • 92
    Krathen RA, Hsu S. Failure of omalizumab for treatment of severe adult atopic dermatitis. J Am Acad Dermatol 2005;53:338340.
  • 93
    Lane JE, Cheyney JM, Lane TN, Kent DE, Cohen DJ. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006;54:6872.
  • 94
    Heil PM, Maurer D, Klein B, Hultsch T, Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course - a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010;8:990998.
  • 95
    Volf EM, Au SC, Dumont N, Scheinman P, Gottlieb AB. A phase 2, open-label, investigator-initiated study to evaluate the safety and efficacy of apremilast in subjects with recalcitrant allergic contact or atopic dermatitis. J Drugs Dermatol 2012;11:341346.
  • 96
    Samrao A, Berry TM, Goreshi R, Simpson EL. A pilot study of an oral phosphodiesterase inhibitor (apremilast) for atopic dermatitis in adults. Arch Dermatol 2012;148:890897.
  • 97
    Hanifin JM, Schneider LC, Leung DY, Ellis CN, Jaffe HS, Izu AE et al. Recombinant interferon gamma therapy for atopic dermatitis. J Am Acad Dermatol 1993;28(2 Pt 1):189197.
  • 98
    Jang IG, Yang JK, Lee HJ, Yi JY, Kim HO, Kim CW et al. Clinical improvement and immunohistochemical findings in severe atopic dermatitis treated with interferon gamma. J Am Acad Dermatol 2000;42:10331040.
  • 99
    Moul DK, Routhouska SB, Robinson MR, Korman NJ. Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2008;58:984989.
  • 100
    Simon D, Wittwer J, Kostylina G, Buettiker U, Simon HU, Yawalkar N. Alefacept (lymphocyte function-associated molecule 3/IgG fusion protein) treatment for atopic eczema. J Allergy Clin Immunol 2008;122:423424.
  • 101
    Ibler K, Dam TN, Gniadecki R, Kragballe K, Jemec GB, Agner T. Efalizumab for severe refractory atopic eczema: retrospective study on 11 cases. J Eur Acad Dermatol Venereol 2010;24:837839.
  • 102
    Takiguchi R, Tofte S, Simpson B, Harper E, Blauvelt A, Hanifin J et al. Efalizumab for severe atopic dermatitis: a pilot study in adults. J Am Acad Dermatol 2007;56:222227.